Oxford BioMedica wins second $100 mln gene therapy contract – Nasdaq
Nasdaq |
Oxford BioMedica wins second $100 mln gene therapy contract
Nasdaq LONDON, Feb 15 (Reuters) – Britain'sOxford BioMedica has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion. Oxford Bio said on Thursday it … Oxford BioMedica share price rises on $100m gene therapy deal with Bioverativ Oxford BioMedica signs agreement with Bioverativ |
